Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.

Codiak Biosciences, a US-based exosome therapeutics developer backed by life science real estate investment trust Alexandria Real Estate Equities, has withdrawn its plans for an $86.3m initial public offering.
Douglas Williams, chief executive of Codiak, cited unfavourable market conditions for the company’s decision. Codiak had filed for an IPO in April 2019 and was hoping to list on the Nasdaq Global Select Market.
Founded in 2015, Codiak is working on therapies for cancer, immune-based diseases, metabolic…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in